EANS-News: Sygnis Pharma AG reports on second quarter 2009/2010

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Accounting and Audits/Company Information/Financial Figures/Balance
Sheet/quarterly report/6-month report

Heidelberg (euro adhoc) - Heidelberg, November 10, 2009 - SYGNIS
Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today
published its financial results for the second quarter and the first
half of the fiscal year 2009/2010, which ended on 30 September 2009.

Q2 2009/2010 Financials

• Cash including marketable securities amounted to EUR18.3 million
(EUR11.1 million Q2 08/09), i.e. EUR 2.5 million better than planned.
With the commitment of the US fund YA Global, SYGNIS secures up to
EUR 10 million through a 3 year Standby Equity Distribution Agreement
("SEDA"). Long term financial liabilities amounted to EUR8.0 million
resulting from a loan which is not due for repayment before 2015. •
As a result of expanded research and development activities, total
operating expenses in the second quarter of the fiscal year 2009/2010
increased by EUR0.2 million to EUR2.4 million compared to the same
period of the last fiscal year, i.e. EUR 1.1 million less than
planned. • The net loss in the first half of the fiscal year
2009/2010 amounted to EUR -6.9 million (EUR -3.6 million first half
08/09). • Due to the fall in the market value of the debt securities
unrealized exchange rate losses of EUR 2,6 million have been posted
through profit or loss; these unrealized exchange rate losses were
recorded under equity in the past without effecting income and do not
result in any additional outflow of liquidity.

Operational Highlights

With the SEDA closed with Yorkville in October, SYGNIS secured up to
EUR 10 million, which SYGNIS has the right to request from Yorkville
within the next 3 years.

The phase II efficacy study of SYGNIS´ lead compound AX200 is being
advanced and the development of the preclinical projects, in
particular regarding KIBRA and the neural stem cell program (NSD), is
proceeding during the first half of the fiscal year as planned.
SYGNIS is confident that, based on the results achieved so far, the
anticipated milestones and project goals will be fulfilled providing
a sound basis for further discussions on potential cooperation and
licensing opportunities.

Outlook

With the current financial situation and with regard to the recent
commitment from Yorkville to invest up to EUR 10 million, SYGNIS has
a good financial basis for its focused development. For the ongoing
fiscal year 2009/2010 SYGNIS expects operational costs and net loss
to be lower than originally anticipated. The net loss for the fiscal
year 2009/2010 is expected to be within the original expectations due
to the recognition of unrealized exchange rate losses of
available-for-sale securities through profit or loss.

The report on the first quarter which ended on June 30, 2009 is
available at the SYGNIS webpage at www.sygnis.de.

About SYGNIS Pharma SYGNIS Pharma AG, headquartered in Heidelberg, is
a specialty pharmaceutical company listed on the Prime Standard of
the German stock exchange. The Company is focused on the research,
development and marketing of innovative therapies for the treatment
of disorders of the Central Nervous System. These include Stroke,
Amyotrophic Lateral Sclerosis (ALS) and neurological disorders
resulting from injuries of the brain or spinal cord. All these
disorders are characterized by the fact that, as the disease
progresses, nerve cells are damaged and die. Although there is great
medical demand, there are currently no or only inadequate treatment
options available.

One of the central elements in this value-creation chain is the
continued development of the existing product pipeline. This is
achieved by testing the Company´s proprietary compounds, which are
already under development in a number of further CNS indications
("line extension"). Within specific R&D programs at SYGNIS, new
pre-clinical drug candidates are identified and evaluated as well as
early-stage projects are initiated for the purpose of partnering.

For further information, please contact:

Dr. Franz-Werner Haas
Vice President Operations
+49 (0) 6221 454 812
franz-werner.haas@sygnis.de

Media-Contact:
Julia Phillips Financial Dynamics
Tel.: +44 (0) 20 7269 7187

### Disclaimer Some statements included in this press release,
relating neither to proven financial results nor other historical
data, should be viewed as forward-looking, i.e. not definite. Such
statements are mainly predictions of future results, trends, plans or
goals. These statements should not be considered to be total
guarantees since given their very nature they are subject to known
and unknown risks and imponderability and can be affected by other
factors as a consequence of which the actual results, plans and goals
of SYGNIS Pharma AG may deviate greatly from the established
conclusions or implied predictions contained in such statements.
SYGNIS does not undertake to publicly update or revise these
statements in the light of new information or future results or for
any other reason. ###

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: SYGNIS Pharma AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Franz-Werner Haas

VP Operations / General Counsel

Tel: +49 (0) 6221-454 812

Email: franz-werner.haas@sygnis.de

Branche: Biotechnology
ISIN: DE0005043509
WKN: 504350
Index: CDAX
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade